{"id":"NCT02640612","sponsor":"Boehringer Ingelheim","briefTitle":"Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis","officialTitle":"Long-term Assessment of Safety, Efficacy, Pharmacokinetics and Immunogenicity of BI 695501 in Patients With Rheumatoid Arthritis (RA): an Open-label Extension Trial for Patients Who Have Completed Trial 1297.2 and Are Eligible for Long-term Treatment With Adalimumab","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-22","primaryCompletion":"2017-11-01","completion":"2017-11-01","firstPosted":"2015-12-29","resultsPosted":"2018-12-05","lastUpdate":"2018-12-05"},"enrollment":430,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"BI 695501","otherNames":[]}],"arms":[{"label":"BI 695501","type":"EXPERIMENTAL"}],"summary":"The main objective of this trial is to provide long-term safety, pharmacokinetics (PK), and immunogenicity data on BI 695501 administered via prefilled syringe in patients with Rheumatoid Arthritis who have completed Trial 1297.2. The primary endpoint thereby is the number (proportion) of patients with drug-related adverse events (AEs) during the treatment phase. The secondary objective in this trial is the assessment of Long-term efficacy of BI 695501 by evaluation of:\n\n* the change from Baseline in DAS28 (ESR) at Week 48\n* the proportion of patients meeting American College of Rheumatology 20% (ACR20) response criteria at Week 48\n* the proportion of patients who meet the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) definition of remission at Week 48\n* the proportion of patients with EULAR response (good response, moderate response, or no response) at Week 48.","primaryOutcome":{"measure":"Percentage of Patients With Drug-related Adverse Events (AEs) During the Treatment Phase","timeFrame":"From the first drug administration until 10 weeks after the last drug administration, up to 58 weeks.","effectByArm":[{"arm":"BI 695501 to BI 695501","deltaMin":21.3,"sd":null},{"arm":"Humira® to Humira®","deltaMin":20.4,"sd":null},{"arm":"Humira® to BI 695501","deltaMin":17.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":26},"locations":{"siteCount":91,"countries":["United States","Bulgaria","Chile","Estonia","Germany","Hungary","Malaysia","Poland","Russia","Serbia","South Korea","Spain","Thailand","Ukraine"]},"refs":{"pmids":["33263165","32363771","31387417"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":225},"commonTop":["Upper respiratory tract infection"]}}